Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 3.90B | 3.66B | 3.37B | 3.22B | 2.71B |
Gross Profit | 2.38B | 2.19B | 2.00B | 1.89B | 1.57B |
EBITDA | 1.28B | 1.22B | 1.01B | 1.04B | 793.81M |
Net Income | 887.87M | 845.04M | 679.09M | 744.85M | 581.78M |
Balance Sheet | |||||
Total Assets | 3.29B | 3.26B | 2.75B | 2.44B | 2.29B |
Cash, Cash Equivalents and Short-Term Investments | 288.27M | 453.93M | 112.55M | 144.45M | 383.93M |
Total Debt | 986.95M | 1.07B | 1.35B | 923.70M | 908.48M |
Total Liabilities | 1.70B | 1.78B | 2.14B | 1.75B | 1.66B |
Stockholders Equity | 1.60B | 1.48B | 608.74M | 689.99M | 632.09M |
Cash Flow | |||||
Free Cash Flow | 798.08M | 772.88M | 394.15M | 636.00M | 540.44M |
Operating Cash Flow | 929.00M | 906.51M | 542.98M | 755.55M | 648.06M |
Investing Cash Flow | -207.06M | -125.25M | -195.35M | -292.97M | -109.38M |
Financing Cash Flow | -878.07M | -442.00M | -370.94M | -697.41M | -248.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $43.48B | 49.96 | 59.33% | ― | 5.56% | 4.66% | |
75 Outperform | $33.94B | 29.47 | 18.88% | 0.81% | 0.56% | -4.08% | |
71 Outperform | $17.60B | 26.81 | 40.82% | ― | 2.57% | 8.31% | |
71 Outperform | $19.03B | 20.43 | 13.65% | 1.80% | 12.58% | 13.00% | |
67 Neutral | $12.02B | 39.32 | 3.82% | 0.27% | 1.62% | 78.53% | |
65 Neutral | $26.13B | 31.36 | -680.23% | ― | 1.18% | 12.34% | |
52 Neutral | $7.60B | 0.10 | -62.94% | 2.08% | 16.16% | 0.34% |
On July 10, 2025, IDEXX Laboratories announced the election of Joseph L. (Jay) Hooley to its Board of Directors as an independent Class III Director, expanding the board from nine to ten members. Hooley, a former Chair and CEO of State Street Corporation, brings extensive strategic and financial leadership experience, which is expected to enhance the board’s effectiveness. His election reflects IDEXX’s commitment to strengthening its governance as it continues to innovate in the pet healthcare industry.
The most recent analyst rating on (IDXX) stock is a Buy with a $575.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.
On May 7, 2025, IDEXX Laboratories, Inc. made significant amendments to its corporate governance structure. The company filed a Certificate of Elimination to remove the designation of its Series A Junior Participating Preferred Stock and amended its Certificate of Incorporation to eliminate supermajority voting provisions and allow officer exculpation as per Delaware law. Additionally, the company updated its By-Laws to reflect these changes and establish Delaware courts as the exclusive forum for certain legal actions. These amendments, approved during the 2025 Annual Meeting, aim to streamline corporate governance and align with current legal standards, potentially impacting shareholder engagement and corporate decision-making processes.